

AD _____

Award Number: DAMD17-01-1-0805

TITLE: NSAIDS and the Osteogenic Response to Mechanical Stress in Premenopausal Women

PRINCIPAL INVESTIGATOR: Wendy M. Kohrt, Ph.D.

CONTRACTING ORGANIZATION: University of Colorado
Health Sciences Center
Aurora, CO 80045-0508

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050407 179

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2004	3. REPORT TYPE AND DATES COVERED Annual (20 Sep 2003 - 19 Sep 2004)	
4. TITLE AND SUBTITLE NSAIDS and the Osteogenic Response to Mechanical Stress in Premenopausal Women			5. FUNDING NUMBERS DAMD17-01-1-0805	
6. AUTHOR(S) Wendy M. Kohrt, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Colorado Health Sciences Center Aurora, CO 80045-0508 E-Mail: wendy.kohrt@uchcs.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) This is a study of the effects of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), on the osteogenic response to 9 months of exercise training in healthy, premenopausal women, aged 21 to 40 years (N=102). The hypotheses are: H1 _a : taking short-acting NSAIDS before exercise will diminish increases in bone mineral density (BMD) in response to exercise training H1 _b : taking short-acting NSAIDS after exercise will not diminish the increases in BMD in response to exercise training Participants take either ibuprofen (400mg) or placebo capsules before and after each exercise session. Women are randomized to three treatment arms: 1) NSAID before exercise, placebo after exercise (NSAID/placebo; n=34); 2) placebo before exercise, NSAID after exercise (placebo/NSAID; n=34); and 3) placebo before exercise, placebo after exercise (placebo/placebo; n=34). Eighty-four subjects have completed baseline testing and have been enrolled in the study. Twelve subjects are presently scheduled for or are undergoing baseline testing. These studies could lead to the development of new strategies to reduce the incidence of, and treatment for, stress fractures that occur in response to vigorous physical activity.				
14. SUBJECT TERMS Exercise, stress fracture, ibuprofen, prostaglandins, bone mineral density, estrogen			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	5
Appendices	
Table 1.....	6
Table 2.....	6
Table 3.....	6
Table 4.....	7
Table 5.....	7
Table 6.....	8
Table 7.....	8

INTRODUCTION:

The primary aim of this randomized, double-blinded, placebo-controlled trial is to determine the effects of NSAID (ibuprofen) use on the osteogenic response to 9 months of exercise training in 102 women. The scientific rationale for this study centers on the knowledge that the osteogenic response to mechanical stress is a prostaglandin (PG)-dependent process and that NSAIDs inhibit PG synthesis. There is evidence that regular NSAID use inhibits the normal bone formation response to mechanical loading, increases risk of fracture, and impairs bone healing. The approved statement of work for this project includes 4 years of recruiting, testing, and training subjects as well as completing sample assays, data analysis, and manuscripts.

BODY:

The major objectives for year 3 were to continue enrollment and performance of tests and procedures and to continue assays of biochemical markers on bone turnover and sex hormones. Table 1 is a presentation of the projected and actual enrollment to date in year 3 of the study. Although the date of award was September 20, 2001, there was a stipulation that work could not commence until IRB and HSRRB review and approval processes were completed. The fully executed agreement was signed on January 31, 2002. Therefore, the expected and actual progression displayed in Table 1 is based on a January 31 start date. Thus, in Tables 1 and 2, month 1 of Year 3 is February 2004.

The progression of the study remains largely determined by the rate of enrollment of subjects and their completion of the intervention. Enrollment is defined as being randomized to study medication and start of the intervention. As shown in Table 1, the number of subjects enrolled in the study is slightly behind the projected enrollment (84 vs 90), but we are making a major recruitment effort to complete study enrollment on schedule, by the end of 2004. There are currently 12 subjects undergoing screening and baseline testing for study participation. The number of finishers is also slightly behind the projected number (43 vs 47; Table 2) due to a higher than expected number of dropouts. The reason for the higher dropout rate is not known. However, in several cases, participants indicated they could not continue in the study because of changes in work-related activity (e.g., job stress, unemployment), which may reflect the depressed economic environment in Colorado. Because the goal is to have 25 finishers in each of the 3 treatment groups, we plan to enroll an extra 6 to 9 volunteers to ensure that we meet this goal.

Table 3 outlines the success of the various recruitment methods that have been employed. Since the last report, 260 phone screens and 50 orientation visits have been conducted. Table 4 illustrates that we are close to projected goals concerning race and ethnicity. New recruitment efforts will continue to target minority populations to increase diversity of enrolled subjects. We do this primarily by advertising in newspapers that target minority populations.

Body composition and bone mass data have been analyzed and computerized for 41 of the current 43 finishers (Table 5). When pooled across treatment groups, there is a significant decrease in fat mass and increase in fat-free mass and BMD in regions of the proximal femur. These preliminary findings indicate that the exercise program is sufficient for generating an osteogenic response, which is critical for determining

whether the response is attenuated by NSAID use. At this stage of the project, all indications are that the study is progressing as planned. No changes to the protocol are planned.

The third goal of year 3 of the study was to continue assays of biochemical markers of bone turnover and sex hormones. During year 2 we purchased a new ELISA plate reader and completed preliminary assays to establish the reliability of measurements. All samples for an individual participant in the study are being analyzed in batch. Serum concentrations of sex hormones, gonadotropins, and markers of bone turnover for 28 finishers are reported in Table 6. The values represent samples acquired during the month before and the final month of the exercise intervention, from the early follicular phase and the luteal phase (x2) of the menstrual cycle.

In the review of the last Annual Report, it was suggested that the progress report should include a summary of dietary records and measurements of maximal oxygen consumption (VO₂max), which are reported in Table 7. These data indicate that energy and nutrient intake are remaining constant over the period of study and that the exercise program is sufficiently intense to generate a significant increase in VO₂max.

KEY RESEARCH ACCOMPLISHMENTS:

Consistent with the Statement of Work, the investigators remain blinded to treatment status for all participants. Therefore, there are no treatment-specific study results to report. The key accomplishments to date have been recruiting, enrolling, and testing subjects, and beginning hormone and biomarker assays. Participant enrollment is slightly behind schedule, but we expect to complete enrollment on time through increased recruitment efforts. Because there have been 7 more dropouts than had been projected for this point of the study, we plan to enroll 6 to 9 additional volunteers.

REPORTABLE OUTCOMES:

none

CONCLUSIONS:

Conclusions cannot yet be drawn because the investigators remain blinded to treatment status.

REFERENCES:

none

APPENDICES:

TABLE 1. Year three projected and actual enrollment

	Month											
	1*	2	3	4	5	6	7	8	9	10	11	12
Projected [†]	69	72	75	78	81	84	87	90	93	96	99	102
Actual [†]	67	68	72	73	76	79	81	84	89[‡]	95	99	102

* month 1 is February 2004

[†] numbers represent the cumulative number of enrollees at the end of each month

[‡] bold, italicized numbers are projections through January, 2005

TABLE 2. Year three projected and actual finishers and dropouts

	Month											
	1*	2	3	4	5	6	7	8	9	10	11	12
Projected finishers	32	34	36	38	40	42	45	47	49	51	53	55
Projected dropouts	11	11	12	13	13	14	15	16	16	17	18	18
Actual finishers	31	33	35	37	38	40	42	43	45[‡]	48	51	53
Actual dropouts	12	14	15	18	18	20	23	23	24	24	25	25

* month 1 is February 2004

[†] numbers represent the cumulative number of finishers and dropouts at the end of each month

[‡] bold, italicized numbers are projections through January, 2005

TABLE 3. Recruitment efforts

Recruiting Media	Number of Phone Screens	Number of Orientations
Flier	81	18
Newspapers	144	36
Electronic ads	215	61
Word of mouth	73	24
Not specified	70	6
TOTAL	583	145

TABLE 4. Projected and actual enrollment by ethnicity and race

Race/Ethnic Category	Actual Current Enrollment	% Total	Projected Total Enrollment	% Total
RACE				
American Indian/ Alaskan Native	3	4	1	1
Asian	2	2	3	3
Native Hawaiian/Other Pacific Islander	0	0	0	0
Black/African American	2	2	6	6
White	70	84	92	90
Other/Hispanic	7	8	0	0
Total	84		102	
ETHNICITY				
Hispanic	10	12	20	20
Non-Hispanic	74	88	82	80
Total	84		102	

TABLE 5. Body composition, bone mineral content (BMC), and bone mineral density (BMD) of 42 participants before and after 9 months of exercise training.

	before	after	change	p value
Age, yr	33 ± 5			
Height, cm	166 ± 7			
Weight, kg	66.8 ± 9.6	65.4 ± 8.8	-1.4 ± 2.5	0.0005
Fat-free mass, kg	44.7 ± 5.1	45.4 ± 4.9	0.6 ± 1.3	0.0037
Fat mass, kg	22.0 ± 6.5	20.0 ± 6.0	-2.0 ± 2.0	<0.0001
Total body BMC, g	2327 ± 332	2328 ± 333	1 ± 37	0.9119
BMD, g/cm ²				
total body	1.159 ± 0.100	1.163 ± 0.098	0.004 ± 0.022	0.2565
lumbar spine	1.115 ± 0.139	1.113 ± 0.136	-0.002 ± 0.019	0.6017
total hip	0.976 ± 0.114	0.983 ± 0.112	0.007 ± 0.016	0.0056
femoral neck	0.892 ± 0.123	0.891 ± 0.124	-0.001 ± 0.025	0.8127
trochanter	0.752 ± 0.099	0.758 ± 0.099	0.006 ± 0.014	0.0091
femoral shaft	1.137 ± 0.141	1.150 ± 0.138	0.013 ± 0.023	0.0006

TABLE 6. Sex hormone profiles and markers of bone turnover measured in the early follicular phase (EFP) and twice during the luteal phase (LP1, LP2) of the menstrual cycle before and after exercise training.

	before			after		
	EFP	LP1	LP2	EFP	LP1	LP2
E2, pg/mL	61 ± 26	105 ± 95	93 ± 66	61 ± 20	89 ± 69	91 ± 61
P4, ng/mL	0.4 ± 0.2	4.4 ± 4.6	4.6 ± 4.9	0.5 ± 0.3	3.9 ± 4.5	4.2 ± 4.7
SHBG, nmol/L	281 ± 154	326 ± 203	314 ± 194	267 ± 150	297 ± 177	303 ± 171
FSH, IU/L	3.4 ± 3.1	1.7 ± 1.6	1.8 ± 2.8	2.9 ± 1.4	1.9 ± 1.7	1.8 ± 2.0
LH, IU/L	5.1 ± 3.3	7.5 ± 9.5	4.1 ± 4.5	5.1 ± 3.5	4.6 ± 3.4	4.1 ± 3.8
CTx, ng/mL	0.4 ± 0.2	0.3 ± 0.1	0.4 ± 0.2	0.5 ± 0.2	0.4 ± 0.1	0.4 ± 0.2
BAP, U/L	20.5 ± 5.7	22.3 ± 7.9	25.1 ± 10.1	23.2 ± 8.3	20.9 ± 6.1	20.0 ± 5.3

E2=estradiol; P4=progesterone; SHBG=sex hormone-binding globulin; FSH=follicle stimulating hormone; LH=luteinizing hormone; CTx=C-terminal telopeptide of type I collagen (bone resorption marker); BAP=bone-specific alkaline phosphatase (bone formation marker)

TABLE 7. Dietary intake and cardiovascular fitness before and after 9 months of exercise training.

	before	after	change	p value
Energy intake, kcal/d	1859 ± 451	1838 ± 481	-21 ± 207	0.5931
protein, g/d	78 ± 24	76 ± 29	-2 ± 13	0.4366
carbohydrate, g/d	228 ± 68	231 ± 58	3 ± 24	0.4302
fat, g/d	69 ± 21	67 ± 23	-2 ± 10	0.2794
Calcium intake, g/d	922 ± 328	935 ± 372	13 ± 129	0.5845
VO2max, mL/min/kg	32.3 ± 4.6	37.1 ± 4.7	4.8 ± 3.2	<0.0001
HRmax, beats/min	189 ± 10	187 ± 9	-2 ± 7	0.0409

VO2max=maximal aerobic power; HRmax=maximal heart rate.